Low‐dose UVA ₁ phototherapy for scleroderma: what benefit can we expect?

Abstract

Our experience allows us to conclude that low-dose UVA(1) phototherapy is a well tolerated option, with excellent results mainly in patients with morphea. This treatment is a valuable contribution to these patients, given the limited therapeutic options available.